4584

Kidswell Bio Corporation

キッズウェル・バイオ株式会社
Pharmaceutical
Kidswell Bio Corporation develops pharmaceutical products for the treatment of pediatric, pediatric, intractable, and Asia-endemic diseases in Japan. Its pipeline products include GBS-001 and GBS-010 for oncology; GBS-007 for ophthalmic disease; and GBS-011 for renal disease. The company pipeline products also include GCT-103 that is indicated for pediatric cerebral palsy; GCT-102 for congenital entero-neuropathy; SQ-104 for osteonecrosis of the femoral head; modified thymidine kinase for glioblastoma; and Gene X for spinal cord injury. The company was formerly known as Gene Techno Science Co.,Ltd. and changed its name to Kidswell Bio Corporation in July 2021. The company was incorporated in 2001 and is headquartered in Chuo, Japan.
← Companies
Price
¥156
Market Cap
¥6.8B
Ent. Value
¥6.0B
Net Cash
¥870M
Shares Out.
43.9M
P / E
—
EV / EBIT
—
P / Book
4.82×
P / NCAV
4.87×
Div. Yield
—
Financials
Metric FY 2025
TDnet 		FY 2024
EDINET ↗ 		FY 2023
EDINET ↗ 		FY 2022
EDINET ↗ 		FY 2021
EDINET ↗
Net Sales ¥6.6B ¥5.1B ¥2.4B ¥2.8B ¥1.6B
Cost of Sales — ¥3.4B ¥1.4B ¥1.3B ¥550M
Gross Profit — ¥1.6B ¥1.0B ¥1.5B ¥1.0B
SG&A — ¥1.6B ¥2.4B ¥2.1B ¥1.9B
Operating Income ¥-138M ¥28M ¥-1.3B ¥-551M ¥-919M
Non-Operating Income — ¥27M ¥7M ¥4M ¥3M
Interest Income — ¥1M ¥0M ¥0M ¥0M
Non-Operating Expenses — ¥50M ¥61M ¥78M ¥36M
Interest Expense — ¥39M ¥36M ¥33M ¥15M
Ordinary Income ¥-374M ¥5M ¥-1.4B ¥-625M ¥-953M
Pre-tax Income — ¥73M ¥-1.4B ¥-656M ¥-534M
Income Taxes — ¥94M ¥2M ¥1M ¥2M
Current Tax — ¥94M ¥2M ¥1M ¥2M
Net Income (owners) ¥-413M ¥-21M ¥-1.4B ¥-657M ¥-535M
Comprehensive Income — ¥107M — — ¥-738M
EBITDA — ¥29M ¥-1.3B ¥-550M ¥-917M
EPS ¥-8.48 ¥-0.52 ¥-40.23 ¥-20.77 ¥-17.35
Shares Outstanding — 43.9M 38.9M 32.1M 31.4M
Shares Issued (total) — 43.9M 38.9M 32.1M 31.4M